Trial of IFN or STl571 before proceeding to allografting for CML?

被引：14

作者：

Hehlmann, R ^{[1
]}

机构：

[1] Univ Heidelberg, Klinikum Mannheim, Med Klin 3, D-68305 Mannheim, Germany

来源：

LEUKEMIA | 2000年 / 14卷 / 09期

关键词：

IFN; STl571; allografting; CML; survival;

D O I：

10.1038/sj.leu.2401874

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Ten-year survival of IFN-treated low risk CML patients is about 40%, and more in cytogenetic responders, Allografting has a cure rate of up to 75%, but is associated with considerable procedure related morbidity and mortality. One out of three or four is likely not to survive. A comparative quantification of survival after BMT and IFN treatment suggests that a trial of IFN (and possibly STI 571) before proceeding to allografting is a viable, and in low risk patients a probably preferable option.

引用

页码：1560 / 1562

页数：3

共 21 条

[1]

APPELBAUM FR, 1995, SEMIN ONCOL, V22, P405

[2] PROLONGED ADMINISTRATION OF INTERFERON-ALPHA IN PATIENTS WITH CHRONIC-PHASE PHILADELPHIA-CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA BEFORE ALLOGENEIC BONE-MARROW TRANSPLANTATION MAY ADVERSELY AFFECT TRANSPLANT OUTCOME [J].

BEELEN, DW ;

GRAEVEN, U ;

ELMAAGACLI, AH ;

NIEDERLE, N ;

KLOKE, O ;

OPALKA, B ;

SCHAEFER, UW .

BLOOD, 1995, 85 (10) :2981-2990

[3]

Druker BJ, 1999, BLOOD, V94, p368A

[4] Genetic instability of cancer cells is proportional to their degree of aneuploidy [J].

Duesberg, P ;

Rausch, C ;

Rasnick, D ;

Hehlmann, R .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (23) :13692-13697

[5]

Gale RP, 1998, BLOOD, V91, P1810

[6]

Giralt S, 2000, BLOOD, V95, P410

[7] EFFECT OF PRIOR INTERFERON-ALFA THERAPY ON THE OUTCOME OF ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA [J].

GIRALT, SA ;

KANTARJIAN, HM ;

TALPAZ, M ;

RIOS, MB ;

DELGIGLIO, A ;

ANDERSSON, BS ;

PRZEPIORKA, D ;

DEISSEROTH, AB ;

CHAMPLIN, RE .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (06) :1055-1061

[8]

GOLDMAN JM, 1993, BLOOD, V82, P2235

[9] Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation [J].

Gratwohl, A ;

Hermans, J ;

Goldman, JM ;

Arcese, W ;

Carreras, E ;

Devergie, A ;

Frassoni, F ;

Gahrton, G ;

Kolb, H ;

Niederwieser, D ;

Ruutu, T ;

Vernant, JP ;

de Witte, T ;

Apperley, J .

LANCET, 1998, 352 (9134) :1087-1092

[10] Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia [J].

Hansen, JA ;

Gooley, TA ;

Martin, PJ ;

Appelbaum, F ;

Chauncey, TR ;

Clift, RA ;

Petersdorf, EW ;

Radich, J ;

Sanders, JE ;

Storb, RF ;

Sullivan, KM ;

Anasetti, C .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (14) :962-968

← 1 2 3 →